- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04131829
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study intends to recruit 2 groups:
- Matched healthy control participants will be imaged with one fMRI at baseline as a no-treatment comparison group; and
- a randomized, double-blind group of unmedicated OCD participants who will be assigned to begin either immediate or placebo-delayed treatment, and who will be imaged with fMRIs at baseline and over the course of treatment with a selective serotonin reuptake inhibitor (SSRI), fluoxetine.
Hypothesis-driven analyses and exploratory analyses will be performed in parallel.
This study will address the following Specific Aims:
- Identification of neural dysconnectivity associated with OCD symptomatology.
- Characterizing neural markers of clinical response to SSRI pharmacotherapy.
- Mapping neural predictors of clinical response to pharmacotherapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yale OCD Research Clinic
- Phone Number: 1-855-623-9253
- Email: ocd.research@yale.edu
Study Contact Backup
- Name: Stephen Kichuk, MPH
- Phone Number: 203-974-7534
- Email: stephen.kichuk@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST
-
Contact:
- Stephen Kichuk, MPH
- Phone Number: 203-974-7534
- Email: stephen.kichuk@yale.edu
-
Contact:
- OCD Research
- Phone Number: 1-855-623-9253
- Email: ocd.research@yale.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion criteria for all groups will include: (i) Adults, Men and women will be included, in a 1:1 ratio; and efforts will be made to recruit racial and ethnic subgroups. Groups will be further matched on age, handedness; and later, in analysis, on educational status and smoking history.
(ii) signed informed consent, approved by the Yale Human Investigations Committee; and (iii) ability and willingness to participate in all study procedures, including clinical assessments and fMRI scans.
- Additional inclusion criteria:
OCD Participants:
(i) a DSM diagnosis of OCD, established as detailed above; (ii) a baseline Y-BOCS of ≥16; (iii) no current psychoactive medication, with the exception of the occasional use of a PRN medication for sleep; (iv) treatment seeking, and clinically appropriate for fluoxetine pharmacotherapy; (v) for women of childbearing potential, not pregnant or intending to become pregnant, and willing to use reliable birth control over the course of the study, either prescribed contraceptive (oral contraceptive, injectable, or implant) or one barrier method (e.g. diaphragm with spermicide, intrauterine device, cervical cap). Women of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy tests at the study baseline and on each scan day appointment prior to the MRI scan.
Healthy Control Participants:
(i) no current DSM diagnosis (by clinician interview confirmed by SCID or MINI); (ii) no documented or clinically suspected family history in a first- or second- degree relative of OCD, Tourette syndrome, hoarding disorder, body dysmorphic disorder, or a compulsive grooming disorder.
Exclusion Criteria:
Exclusion criteria for all groups will include:
(i) any unstable medical, psychiatric, or neurological condition (including active or otherwise problematic suicidality) that may necessitate urgent treatment; (ii) any substance use disorder within the past 6 months; (iii) use of psychotropic medications within the past 8 weeks, with the exception of occasional use of a sleep aid or analgesic; (iv) use of an as-needed sleep aid or prescription analgesic within 3 days of the scan; (v) any history of a primary psychotic disorder or of mania; (vi) any evidence of substance use on urine toxicology testing; (vii) any major neurological disease or history of major head trauma, including concussion with extended loss of consciousness; (viii) pregnancy; (ix) any metal in the body or other contraindication to MRI scanning; (x) severe claustrophobia, back pain, or other condition that may make an extended MR scan difficult or lead to excessive movement during the scan.
- Additional exclusion criteria:
OCD Participants:
(i) past allergy or adverse reaction to fluoxetine or another SSRI, or other clinical contraindication to fluoxetine pharmacotherapy; (ii) documented nonresponse to a past trial of fluoxetine of appropriate dose (≥40 mg/dy) and duration (≥12 weeks).
(iii) Patients taking Coumadin or Monoamine oxidase inhibitors (MAOIs) will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Healthy Controls
The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
|
|
Experimental: OCD Group
The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms.
OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
|
Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Other Names:
Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Obsessive-compulsive severity change
Time Frame: 18 weeks
|
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS);72,73 -This is a checklist and Clinician administered - 10 item severity scale, from none to extreme.
Total severity score range is 0 to 40.
This will be presented as % improvement in Y-BOCS as a continuous measure of treatment response, rather than an artificially dichotomized measure of 'response', in all analyses.
This the primary outcome measure of change across the study treatment and scans.
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tic severity change
Time Frame: 18 weeks
|
Yale Global Tic Severity Scale (YGTSS) will be used to measure Tic severity.
It is a clinician administered instrument with a score from 0 to 25- 25 being the most severe.
|
18 weeks
|
Beck Depression Inventory-II
Time Frame: 18 weeks
|
Beck Depression Inventory-II (BDI-II);82 21 items to assess intensity of depression.
|
18 weeks
|
Anxiety
Time Frame: 18 weeks
|
Beck Anxiety Inventory (BAI);83 21 item self report on a 4 point Likert scale - 0 (not at all) to 3 (severely).
|
18 weeks
|
Obsessive-compulsive concerns
Time Frame: 18 weeks
|
Dimensional Obsessive-Compulsive Scale (DOCS);84 20 questions, asks about 4 categories of obsessive-compulsive concerns (each consists of 5 items scored on a Likert scale of 0-no symptoms to 4 - extreme symptoms) over the previous month.
|
18 weeks
|
Magical ideation
Time Frame: 18 weeks
|
Magical Ideation Scale (MIS);86 30 item true / false scale, assessing erroneous beliefs based on magical thinking.
|
18 weeks
|
Sensory phenomena
Time Frame: 18 weeks
|
University of São Paulo Sensory Phenomena Scale (USP-SPS);87
|
18 weeks
|
"Not Just Right" experiences and sensations in OCD
Time Frame: 18 weeks
|
Not Just Right Experiences Questionnaire Revised (INC).88
19 Questions: Rate 10 NJR Experiences; Choose most recent one; Identify how long ago it occurred; then complete 7 dimensional ratings of that NJRE: frequency, intensity, immediate distress, delayed distress, rumination, urge to respond, and responsibility to do something about the NJRE, from 1 (absence) to 7 (extreme level /or within the past day).
|
18 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher Pittenger, MD, PhD, Professor of Psychiatry; Director, Yale OCD Research Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Anxiety Disorders
- Obsessive-Compulsive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Fluoxetine
Other Study ID Numbers
- 2000023688
- 1R01MH116038-01A1 (U.S. NIH Grant/Contract)
- 1K24MH121571-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on Fluoxetine - immediate treatment
-
NHS LothianKarolinska Institutet; University of EdinburghCompleted
-
Association Francaise pour la Recherche ThermaleUniversity Hospital, Grenoble; FloralisWithdrawnObstructive Sleep Apnea Syndrome | Chronic Venous InsufficiencyFrance
-
Association Francaise pour la Recherche ThermaleFloralisRecruitingLymphoma | Breast Cancer | Prostate Cancer | Lymphoedema | Malignant Disease | Gynaecological CancerFrance
-
Baylor College of MedicineCompletedAttention Deficit and Disruptive Behavior Disorders | Attention Deficit Hyperactivity DisorderUnited States
-
Association Francaise pour la Recherche ThermaleUniversité Joseph Fourier; FloralisCompletedLeg Ulcer | Venous Insufficiency | Varicose UlcerFrance
-
Association Francaise pour la Recherche ThermaleCompleted
-
NYU Langone HealthWithdrawnBreast CancerUnited States
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Tampere University HospitalRecruiting
-
Case Western Reserve UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMultiple SclerosisUnited States